RIGImmune

Executive Summary

RIGImmune is a private biopharmaceutical company pioneering a novel class of immune-modulating RNA therapeutics for respiratory diseases. Founded in 2017 and headquartered in New Haven, Connecticut, the company differentiates itself by combining a proprietary oligonucleotide platform that activates the RIG-I innate immune pathway with a non-lipid nanoparticle (LNP) delivery system. This dual approach aims to deliver RNA directly to the respiratory tract, potentially overcoming the limitations of conventional LNP-based therapies such as storage challenges, immunogenicity, and repeat-dosing constraints. RIGImmune's technology holds promise for treating a range of respiratory infections and inflammatory conditions by harnessing the body's natural antiviral defenses. Despite limited publicly disclosed funding and pipeline details, RIGImmune operates in a high-demand space with significant unmet need. The success of similar RIG-I agonists and non-LNP delivery systems in preclinical studies suggests the platform could attract strategic partnerships or additional financing. However, the company remains at an early stage, with no disclosed clinical trials or regulatory milestones. Its ability to advance into human studies and demonstrate safety and efficacy will be critical. The nascent competitive landscape and technical challenges of non-LNP RNA delivery pose risks, but if successful, RIGImmune could offer a differentiated therapeutic option for respiratory diseases.

Upcoming Catalysts (preview)

• Q4 2026IND-Enabling Studies Initiation for Lead Respiratory Candidate60% success
• Q3 2026Partnership or Licensing Deal for Non-LNP Delivery Platform45% success
• Q4 2026Publication of Preclinical Proof-of-Concept Data in Animal Models70% success